Yuki Oya
Last active: 10/27/2015

Liver transplant from an ABO-incompatible and hepatitis C antibody-positive but an HCV-RNA negative living donor in a familial amyloid polyneuropathy patient.

Takeichi T, Asonuma K, Yamamoto H, Ohya Y, Okumura K, Lee KJ, Inomata Y
Exp Clin Transplant. 2013 11 (2): 182-5

PMID: 23194392 · DOI:10.6002/ect.2012.0158

Familial amyloid polyneuropathy is a rare, progressively disabling, and ultimately fatal inherited disease. Liver transplant is currently the only available treatment proven to halt the progression of familial amyloid polyneuropathy. We report a 31-year-old woman with familial amyloid polyneuropathy who received a living-donor liver transplant from her husband who was hepatitis C virus antibody-positive but HCV-RNA negative and ABO incompatible. Six years after the transplant, both donor and recipient have normal liver biochemistry results; no hepatitis C viral load has been detectable in the recipient. This is the first report of a living ABO-incompatible liver transplant from an anti-hepatitis C virus antibody-positive but an HCV-RNA negative donor. This experience suggests that the use of an anti-hepatitis C virus antibody-positive hepatic graft is possible in select circumstances.

MeSH Terms (15)

ABO Blood-Group System Adult Amyloid Neuropathies, Familial Blood Group Incompatibility Female Hepacivirus Hepatitis C Hepatitis C Antibodies Histocompatibility Testing Humans Liver Transplantation Living Donors Male Spouses Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: